A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
Launched by PFIZER · Dec 22, 2008
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
- • The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory
- • Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity.
- • No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
- • Patient has washed out of all DMARDs other that antimalarials
- Exclusion Criteria:
- • Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3.0 x 109/L; 3. Absolute neutrophil count \<1.2 x 109/L; 4. Platelet count \<100 x 109/L
- • History of any other autoimmune rheumatic disease other than Sjogren's syndrome
- • No malignancy or history of malignancy.
- • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Winston Salem, North Carolina, United States
Hot Springs, Arkansas, United States
Jacksonville, Florida, United States
Tampa, Florida, United States
Frederick, Maryland, United States
Albany, New York, United States
Mesquite, Texas, United States
Tucson, Arizona, United States
Dallas, Texas, United States
Hamburg, , Germany
Venice, Florida, United States
Dayton, Ohio, United States
Porto Alegre, Rs, Brazil
Seattle, Washington, United States
Leipzig, , Germany
Monterrey, Nuevo Leon, Mexico
Muenchen, , Germany
Chihuahua, , Mexico
Duncansville, Pennsylvania, United States
Myrtle Beach, South Carolina, United States
Kuching, Sarawak, Malaysia
Curitiba, Pr, Brazil
Rio De Janeiro, Rj, Brazil
Petrozavodsk, , Russian Federation
Smolensk, , Russian Federation
Kharkiv, , Ukraine
Pune, Maharashtra, India
Olean, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
West Reading, Pennsylvania, United States
Greenville, South Carolina, United States
Warszawa, , Poland
Kalamazoo, Michigan, United States
Minot, North Dakota, United States
Pleven, , Bulgaria
Wroclaw, , Poland
Bethlehem, Pennsylvania, United States
Rockford, Illinois, United States
Manila, , Philippines
Plovdiv, , Bulgaria
Teaneck, New Jersey, United States
Berlin, , Germany
Brno, , Czech Republic
Praha 4, , Czech Republic
Gilbert, Arizona, United States
Bangalore, Karnataka, India
Goiania, Go, Brazil
Praha 2, , Czech Republic
Zlin, , Czech Republic
Warszawa, , Poland
Sarasota, Florida, United States
Sao Paulo, Sp, Brazil
Santo Domingo, , Dominican Republic
Ahmedabad, Gujarat, India
Mangalore, Karnataka, India
San Juan, , Puerto Rico
Vinnitsa, , Ukraine
Berlin, , Germany
Sofia, , Bulgaria
Bucaramanga, Santander, Colombia
Las Piñas City, , Philippines
Providencia, Santiago, Rm, Chile
Kyiv, , Ukraine
Lviv, , Ukraine
Clarksburg, West Virginia, United States
Barranquilla, , Colombia
Sao Paulo, , Brazil
Monterrey, Cp, Mexico
Zephyr Hills, Florida, United States
Hyannis, Massachusetts, United States
Rocky Mount, North Carolina, United States
Santiago, Rm, Chile
Ceska Lipa, , Czech Republic
Hlucin, , Czech Republic
Pardubice, , Czech Republic
Halle, , Germany
Nuernberg, , Germany
Hyderabad, Andhra Pradesh, India
Secunderabad, Andra Pradesh, India
Kota Kinabalu, Sabah, Malaysia
Petaling Jaya, Selangor Darul Ehsan, Malaysia
Putrajaya, Wilayah Persekutuan, Malaysia
Tijuana, Baja California, Mexico
Guadalajara, Jalisco, Mexico
Dasmarinas, Cavite, Philippines
Bajada, Davao City, Phlippines, Philippines
Simferopol, Crimea, , Ukraine
Providencia, , Chile
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials